519MO Phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival analysis
| Autor: | Oaknin, A., Monk, B.J., Polastro, L., Cristina de Melo, A., Kim, H.S., Kim, Y.M., Lisyanskaya, A.S., Samouëlian, V., Lorusso, D., Damian, F.B., Chang, C-L., Takahashi, S., Ramone, D., Maćkowiak-Matejczyk, B., Li, J., Jamil, S., Mathias, M.D., Fury, M.G., Tewari, K.S. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S781-S781 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|